{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:27:37Z","timestamp":1789687657128,"version":"4.0.1"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK\n                    <jats:sup>+<\/jats:sup>\n                    ) in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (EF; \u226540%), and renal impairment. Patients with HF with EF greater than or equal to 40% and estimated glomerular filtration rate of 40\u201370\u2009ml\/min\/1.73\u2009m\n                    <jats:sup>2<\/jats:sup>\n                    were randomized to once\u2010daily AZD9977 100\u2009mg or spironolactone 25\u2009mg for 14\u2009days, up\u2010titrated to AZD9977 200\u2009mg or spironolactone 50\u2009mg for another 14\u2009days. The primary end point was relative change (%) in sK\n                    <jats:sup>+<\/jats:sup>\n                    for AZD9977 versus spironolactone (baseline to day 28). Serum\/urinary electrolytes, fractional excretion (FE) of Na\n                    <jats:sup>+<\/jats:sup>\n                    \/K\n                    <jats:sup>+<\/jats:sup>\n                    , plasma aldosterone, cortisol, and renin, and safety were also assessed. Sixty\u2010eight patients were randomized (AZD9977,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a033; spironolactone,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a035). Mean (SD) age was 73.0 (8.5) years, 51.5% men. Mean sK\n                    <jats:sup>+<\/jats:sup>\n                    change from baseline to day 28 was 5.7% (AZD9977) and 4.2% (spironolactone), and 1.5% and 4.2% at day 14. Relative change (95% confidence interval) in sK\n                    <jats:sup>+<\/jats:sup>\n                    with AZD9977 versus spironolactone was \u22120.3% (\u22125.3% to 4.4%; day 28), and 3.4% (\u22120.8% to 7.5%; day 14). Median increase from baseline in plasma aldosterone at day 28 was 89.8\u00a0pmol\/L for AZD9977 and 67.4\u00a0pmol\/L for spironolactone. Median FE of K\n                    <jats:sup>+<\/jats:sup>\n                    was 12.9% (AZD9977) and 10.1% (spironolactone). AZD9977 was well\u2010tolerated. No discontinuations due to hyperkalemia occurred with either treatment. Evidence of target engagement for AZD9977 with a favorable safety profile, supports further evaluation of AZD9977 in patients with HF and renal impairment.\n                  <\/jats:p>","DOI":"10.1111\/cts.13377","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T01:59:30Z","timestamp":1660615170000},"page":"2493-2504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial"],"prefix":"10.1111","volume":"15","author":[{"given":"Iain B.","family":"Squire","sequence":"first","affiliation":[{"name":"NIHR Biomedical Research Centre Glenfield Hospital  Leicester UK"},{"name":"Department of Cardiovascular Sciences University of Leicester  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Gabrielsen","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-4477","authenticated-orcid":false,"given":"Peter J.","family":"Greasley","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wernevik","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hartleib\u2010Geschwindner","sequence":"additional","affiliation":[{"name":"Late\u2010stage Development, Cardiovascular, Renal, and Metabolism BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Holden","sequence":"additional","affiliation":[{"name":"Global Drug Safety, Oncology R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Johansson","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudvik","sequence":"additional","affiliation":[{"name":"Early Biometrics and Statistical Innovation, Data Science and AI BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Early Biometrics and Statistical Innovation, Data Science and AI BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Bamberg","sequence":"additional","affiliation":[{"name":"Translational Sciences and Experimental Medicines, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Melin","sequence":"additional","affiliation":[{"name":"Clinical &amp; Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Whittaker","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals R&amp;D, AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00313"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.48"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.09.007"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2018.03.002"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.11.015"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013255"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv464"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1909"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.07.010"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.217"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1199"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193380"},{"key":"e_1_2_11_18_1","first-page":"999","article-title":"MR modulator AZD9977 causes reduced plasma potassium elevation compared to eplerenone after potassium challenge in CKD model","volume":"29","author":"Bamberg K","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1612601"},{"key":"e_1_2_11_21_1","unstructured":"Data on file. AstraZeneca."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00608404"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c130044"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:08:42Z","timestamp":1692706122000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/cts.13377"],"URL":"https:\/\/doi.org\/10.1111\/cts.13377","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"2022-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}